Fighting cancer with next generation cell and gene therapies and a universally compatible CAR T-cell technology platform

Our technology
iTANK-platform Our pipeline
CAR T-cells and oncolytic viruses

News

January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

January 14, 2022

Regulatory Press Release

Press Release

News

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

January 5, 2022

Regulatory Press Release

Press Release

News

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

All news

Get to know Elicera Therapeutics

Elicera's strengths are based on a deep understanding of how cells and viruses can be genetically engineered to trigger a powerful immune response to cancer.

Di Yu, Head of Technical Operations and co-founder, tells more about Elicera in the film.

About Elicera

iTANK-technology platform

A universal CAR T-cell technology platform, compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

iTANK-platform

Ongoing clinical study

Uppsala University is currently sponsoring an ongoing clinical phase I/II-study with Elicera's oncolytic virus, ELC-100, in neuroendocrine tumors. In addition, a second clinical phase I/II-study with CAR T-cell therapy, ELC-301, in B-cell lymphoma, is under planning.

Technology Pipeline

Scientist working with vaccines in a lab

Company Presentation

See the latest company presentation.

Events and Presentations

Sign up for Press Releases

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.